Published in Am J Kidney Dis on November 01, 2010
Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol (2011) 3.68
Prevalence of hypertension, obesity, diabetes, and metabolic syndrome in Nepal. Int J Hypertens (2011) 1.54
Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One (2016) 1.17
The epidemiology of chronic kidney disease in Northern Tanzania: a population-based survey. PLoS One (2015) 0.98
Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open (2012) 0.94
Rictor/mTORC2 signaling mediates TGFβ1-induced fibroblast activation and kidney fibrosis. Kidney Int (2015) 0.91
Blood lead and cadmium levels and renal function in Korean adults. Clin Exp Nephrol (2013) 0.87
Knowledge, Attitudes, and Practices Associated with Chronic Kidney Disease in Northern Tanzania: A Community-Based Study. PLoS One (2016) 0.78
Epidemiology of chronic kidney disease, with special emphasis on chronic kidney disease of uncertain etiology, in the north central region of Sri Lanka. J Epidemiol (2015) 0.77
Elevated levels of protein in urine in adulthood after exposure to the Chinese famine of 1959-61 during gestation and the early postnatal period. Int J Epidemiol (2014) 0.77
Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest (2014) 0.77
Apobec-1 Complementation Factor (A1CF) Inhibits Epithelial-Mesenchymal Transition and Migration of Normal Rat Kidney Proximal Tubular Epithelial Cells. Int J Mol Sci (2016) 0.76
Omega-3 Polyunsaturated Fatty Acids Attenuate Fibroblast Activation and Kidney Fibrosis Involving MTORC2 Signaling Suppression. Sci Rep (2017) 0.75
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med (2009) 12.73
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol (2006) 6.21
Atypical hemolytic-uremic syndrome. N Engl J Med (2009) 5.66
Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet (2012) 5.65
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med (2004) 4.72
Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ (2011) 4.68
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med (2009) 4.35
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol (2010) 3.82
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int (2009) 3.70
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet (2005) 3.52
Recommendations on screening for type 2 diabetes in adults. CMAJ (2012) 3.51
Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med (2011) 3.49
How does proteinuria cause progressive renal damage? J Am Soc Nephrol (2006) 3.46
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol (2004) 3.41
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med (2009) 3.24
Hemolytic uremic syndrome. J Am Soc Nephrol (2005) 3.19
Early recognition and prevention of chronic kidney disease. Lancet (2010) 3.19
Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med (2011) 3.17
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation (2005) 3.10
Delayed graft function in kidney transplantation. Lancet (2004) 3.06
Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int (2013) 3.05
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int (2005) 3.03
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet (2010) 2.95
Decision time for pancreatic islet-cell transplantation. Lancet (2008) 2.91
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int (2008) 2.88
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Familial haemolytic uraemic syndrome and an MCP mutation. Lancet (2003) 2.79
Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet (2003) 2.71
Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nat Rev Nephrol (2013) 2.66
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Physician awareness of drug cost: a systematic review. PLoS Med (2007) 2.63
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol (2007) 2.61
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int (2008) 2.56
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice. Stem Cells (2008) 2.51
Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest (2009) 2.49
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med (2011) 2.48
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. Arch Pediatr Adolesc Med (2003) 2.47
Rates of treated and untreated kidney failure in older vs younger adults. JAMA (2012) 2.43
Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review. Am J Kidney Dis (2004) 2.43
Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol (2010) 2.42